For those studying how synthetic GLP-1 agonists might perform under simulated glucose load or behavioral conditioning models, this formulation presents a structured and reliable entry point
Disclosures: Abdellatif Ismail: Nothing to Disclose, Winston Dunn: Nothing to Disclose, Gene Im: KorroBio: Consultant, Echosens: Device support for research, Ethan Weinberg: PharmaIN: Consultant, BioVie: Consultant, Sequana: Consultant, Novo Nordisk: Advisor, Allison Kwong: Nothing to Disclose, Ana Clemente: Nothing to Disclose, Shasthry Sm: Nothing to Disclose, Archana Rastogi: Nothing to Disclose, Bethany So: Nothing to Disclose, Kevin Tang: Nothing to Disclose, Rashmi Tondon: Nothing to Disclose, Suvradeep Mitra: Nothing to Disclose, Nipun Verma: Nothing to Disclose, Ajay Duseja: Nothing to Disclose, Rohit Mehtani: Nothing to Disclose, Paul Kwo: Nothing to Disclose, K Rajender Reddy: Nothing to Disclose, Ramon Bataller: Nothing to Disclose, Juan Pablo Arab: Nothing to Disclose, Patrick Kamath: Sequana: Advisor, NovoNordisk: Advisor, Shiv Kumar Sarin: Nothing to Disclose, Ashwani Singal: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose 709 CLINICAL FACTORS IMPACTING THE HEALTH-RELATED QUALITY OF LIFE OF CHILDREN AND YOUNG ADULTS WITH AUTOIMMUNE LIVER DISEASE Rebecca Farr 1 Lin Fei 1 Rashmi Sahay 1 Heidi Kalkwarf 1 Kevin Hommel 1 Cyd Castro-Rojas 1 Mosab Alquraish 1 Amy Taylor 1 Alexander Miethke 1 , 1 Cincinnati Children's Hospital Medical Center Background Pediatric autoimmune liver disease (AILD) is a spectrum of rare, chronic liver diseases, ranging from autoimmune hepatitis (AIH) to primary sclerosing cholangitis (PSC)
Both exert their effects through activation of the GLP-1 receptor (GLP-1R)
Contact your doctor should symptoms persist or become more intense
-1.jpg)
